B
y using model organisms such as the mouse, developmental biologists have uncovered requirements for discrete signaling pathways and precise spatiotemporal coordination during early embryonic development and organogenesis 1 . These findings form the basis for guided differentiation of human ESCs (hESCs) or human induced pluripotent stem cells (hiPSCs) into the three embryonic lineages and their derivatives 2 . On the other hand, CRISPR/CRISPR-associated (Cas)-mediated genome editing in hESCs/hiPSCs combined with guided differentiation offers a valuable platform to investigate human development. For instance, the guided differentiation of hESCs/hiPSCs into definitive endoderm (DE) is induced by Activin A 3 . This mimics the action of Nodal, a member of the transforming growth factor (TGF)-β superfamily known to signal via the SMAD2-SMAD3-SMAD4-FOXH1 complex to promote endoderm differentiation in gastrulating mouse embryos 4 . Using Activin A-induced DE differentiation and reverse genetics in hESCs, we and others have previously demonstrated critical requirements for the transcription factors (TFs) EOMES and GATA6 in the formation of human endoderm [5] [6] [7] [8] . Despite some progress, much remains to be learned about mammalian embryonic development, especially human development. Notably, endoderm differentiation and pluripotency maintenance both involve the Nodal-TGF-β pathway 3, [9] [10] [11] . It is unclear how hESCs interpret TGF-β signaling in two opposing ways: promoting self-renewal and promoting endoderm differentiation. Thus, an unknown inhibitory mechanism has been postulated as a way to prevent hESCs from precociously differentiating into endoderm cells 12 . In addition, differentiation efficiencies vary among hESC/ hiPSC lines 13, 14 , and homogeneous differentiation remains a major challenge, highlighting the need for discovering additional regulatory mechanisms that control DE differentiation.
Forward genetic screens in model organisms provide a powerful approach for uncovering previously unsuspected regulators of development 1 . The key endoderm regulator Nodal was itself first identified in a genetic screen performed in mice 15 . However, this approach is not directly applicable to studies of human embryogenesis, posing a challenge for identifying unique regulatory mechanisms underlying the developmental control of the human genome. Here we conducted genome-scale CRISPR/Cas screens for high-throughput discovery of regulators of DE differentiation. In addition to known regulators of DE differentiation, we identified genes including five essential Jun N-terminal kinase (JNK)-JUN pathway genes that inhibit DE differentiation. The JNK-JUN pathway is not required for the maintenance of the pluripotent state. Instead, JNK inhibition specifically accelerates the decommissioning of ESC enhancers during DE differentiation and promotes the reconfiguration Significance is indicated as: *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001. i, A summary of the number of tested and verified hits.
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of SMAD2 and SMAD3 (SMAD2/3) binding to DE enhancers cobound by GATA6. Thus, the JNK-JUN pathway constitutes a key barrier from pluripotency to DE differentiation. Our findings demonstrate the power of large-scale forward genetic screens for uncovering genes that regulate hESC/hiPSC differentiation and human development. Moreover, JNK inhibitor (JNKi) treatment improves DE and DE-derived pancreatic and lung lineage differentiation, and reduces the dose requirement for Activin A, highlighting the potential of harnessing the knowledge gained from developmental studies for regenerative medicine.
Results
Genome-scale knockout screens using pooled CRISPR libraries. To screen for regulators of DE differentiation, we used the HUES8 iCas9 hESC line, which expresses Cas9 on doxycycline treatment 16 ( Supplementary Fig. 1a ). We further employed a selection-free knock-in strategy 17 to integrate a green fluorescent protein (GFP) transgene into the SOX17 locus to report endoderm fate 18 ( Supplementary Fig. 1b,c) . Both Activin A and CHIR99021 were required to induce CXCR4 + SOX17
+ (~80%) DE cells (Fig. 1a,b) , and faithful GFP reporter expression was confirmed by immunostaining and flow cytometry ( Supplementary Fig. 1d ,e). As a positive control, the requirement for EOMES in DE differentiation 5, 19 was confirmed by performing differentiation on HUES8 SOX17 GFP/+ iCas9 hESCs infected with a lentivirus expressing an EOMEStargeting guide RNA (gRNA; Supplementary Fig. 1f ).
We first performed the screen using the pooled lentiviral human GeCKO v.2 library consisting of 58,028 gRNAs targeting 19,009 genes (three gRNAs per gene) 20 . To improve the confidence of screening hits, we then repeated the screen using a serum-free differentiation condition with the Brunello library 21 consisting of 76,441 gRNAs targeting 19,114 genes (four gRNAs per gene). After infection of HUES8 SOX17 GFP/+ iCas9 hESCs with the lentiviral gRNA libraries, DE differentiation was performed. SOX17-GFP + endoderm and SOX17-GFP -non-endoderm cells were isolated through FACS (Fig. 1c) . The abundance of individual gRNAs in each population was determined by high-throughput sequencing.
Two approaches were used to identify and rank hits. We first calculated the Z-score 22 for each gRNA based on the ratio of gRNA reads in the SOX17-GFP -versus SOX17-GFP + populations ( Supplementary Fig. 2a,b) . Thirty-seven positive regulators and 28 negative regulators exceeded the absolute Z-score cutoff (|Z-score| > 2) in both screens (Fig. 1d, Supplementary Fig. 2c and Supplementary Dataset 1). In the second approach, we used the MAGeCK robust ranking aggregation (RRA) algorithm to identify screening hits 23 . RRA values from the two screens correlated well (Fig. 1e,f) . All 27 genes with a false discovery rate (FDR) lower than 0.05 in both screens met the Z-score cutoff (|Z-score| > 2.0; Fig. 1e ,f and Supplementary Dataset 1). The theoretical FDR predicted by MAGeCK from the GeCKO library screen is consistent with the experimental FDR replicated in the Brunello library screen ( Supplementary Fig. 2d ). The top-ranked positive regulator hits based on both methods included almost all non-redundant, cellautonomously required genes in the Nodal pathway (ACVR1B, SMAD2, SMAD4 and FOXH1), as well as established endoderm TFs (EOMES and MIXL1) ( Fig. 1d and Supplementary Fig. 2c ) 4, 24 .
Validation of screening hits. We performed validation experiments on 33 high-ranking hits based on the Z-score and FDR (Supplementary Table 1 ). Lentiviral vectors expressing gene-specific gRNAs were used to infect H1 iCas9 hESCs followed by individual differentiation assays, and two gRNAs were tested for each gene ( Fig. 1g and Supplementary Fig. 3a ). We were able to verify endoderm TF genes including EOMES, MIXL1 and genes in Nodal and Wnt signaling pathways, consistent with their known requirements in mice 19, [25] [26] [27] [28] [29] [30] (Fig. 1h ). In addition, we verified four Hippo pathway genes (NF2, TAOK1, PTPN14 and PPP2R4) known to negatively regulate YAP1 nuclear activity (Fig. 1h) . Previous studies showed that transient short interfering RNA knockdown of YAP1 expression in hESCs led to upregulation of mesendoderm genes MIXL1, EOMES and T 31, 32 , but a specific requirement of YAP1 or other Hippo pathway members in DE formation has not been established. Supporting the high confidence in the top screening hits, we validated 24 genes out of 33 hits tested (Fig. 1i) . Screening hits that were not verified are probably false positives, as also found in other large-scale screening studies, although more thorough examinations may be necessary to confirm hits with relatively subtle phenotypes ( Supplementary Fig. 3b ). Only 4 of the 24 genes showed greater than twofold gene expression changes during the ESC-DE transition by RNA-sequencing (RNA-seq) analysis (Supplementary Fig. 3c and Supplementary Dataset 2). This highlights the necessity for comprehensive functional analysis rather than relying on transcriptome analysis alone.
The JNK pathway inhibits DE differentiation. Four of the six negative regulator hits with FDR < 0.05 in both screens are core members of the mitogen-activated protein kinase (MAPK) JNK pathway, including the MAPK kinase kinase MEKK1 (MAP3K1), the MAPK kinase MKK4 (MAP2K4) and MKK7 (MAP2K7), and the AP-1 family TF JUN (C-JUN) (Figs. 1f and 2a) . A fifth JNK pathway gene JNK1 (MAPK8) just missed the FDR cutoff (Brunello screen FDR < 0.05, GeCKO screen FDR = 0.056). In addition, two subunits (ARID1A, SMARCC1) of the SWI/SNF chromatin remodeling complex, which has been proposed to be a critical co-activator for AP-1 transcription factors 33 , were also identified as negative regulators. The JNK-JUN pathway can be activated by a variety of environmental signals including stress, cytokines and growth factors 34 , but it has not been reported to regulate DE differentiation. Using lentiviruses expressing gene-specific gRNAs, we were able to validate the inhibitory effects of all five JNK pathway genes on DE differentiation (Figs. 1h and 2a) . We further generated clonal H1 MKK7 and JUN knockout (KO) lines and verified the KOs by western blotting (Fig. 2b,c and Supplementary Fig. 4a ). We confirmed that MKK7 KO cells had greatly reduced JNK phosphorylation, undetectable levels of JUN phosphorylation, and reduced JUN expression because of loss of positive autoregulation 35 ( Fig. 2c) . MKK7 or JUN KO cells did not exhibit a difference in cell growth during hESC self-renewal or DE differentiation ( Supplementary  Fig. 4b ), nor did flow cytometry detect a significant difference in the number of cells expressing proliferation or apoptosis markers (phospho-histone H3 and cleaved caspase-3, respectively) during differentiation ( Supplementary Fig. 4c ). MKK7 and JUN KO hESCs formed neuroectoderm cells 36 expressing PAX6 and SOX1 with comparable efficiency and kinetics to the wild-type (WT) control (Supplementary Fig. 5a-d) . In contrast, MKK7 and JUN KO cells readily formed DE cells expressing CXCR4, SOX17, GATA6 and GATA4 at a higher efficiency compared with isogenic WT controls (Fig. 2d,e) . RNA-seq analysis showed significant global transcriptional differences between WT and MKK7 KO cells at the DE, but not the ESC stage ( Fig. 2f and Supplementary Dataset 3) , as verified using a panel of DE and ESC markers for flow cytometry, immunostaining and reverse transcription-quantitative PCR (RT-qPCR) ( Supplementary Fig. 4d-g ). These findings demonstrate that the JNK-JUN pathway inhibits the ESC-DE transition but does not affect pluripotency maintenance.
Pharmacological JNK inhibition improves DE differentiation.
We tested the effects of JNK-IN-8 (ref. 37 ), a selective JNKi, on DE differentiation (Fig. 3a) . Western blotting analysis confirmed that JUN phosphorylation was barely detectable in JNKi-treated H1 hESCs (Fig. 3b) . Similar to genetic perturbation, JNKi treatment improved the efficiency of DE differentiation to >90% based 
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on flow cytometry analysis for expression of key endoderm genes including CXCR4, SOX17, GATA6 and GATA4, and confirmed by the corresponding RT-qPCR analysis ( Fig. 3c and Supplementary  Fig. 6a ). JNKi also significantly increased DE differentiation efficiency in additional hESC (HUES8 and HUES6) and hiPSC (BJ and CV) lines ( Supplementary Fig. 6b,c ). These findings demonstrate that JNK inhibition improves DE differentiation efficiency and reduces differentiation variability.
We performed Drop-Seq 38 and conducted unsupervised hierarchical clustering on 1,604 and 1,732 individual DE cells from control and JNKi-treated conditions, respectively, using a panel of DE and ESC marker genes (Fig. 3d) or the 1,000 most variably expressed genes ( Supplementary Fig. 6d ). JNKi treatment during differentiation induced a relatively homogenous cell population, in which DE signature genes were highly expressed and ESC signature genes were low to undetectable. In comparison, the control differentiation condition resulted in two cell populations: one expressing DE signature genes, which clustered closely with cells from the JNKi condition, and the other retaining some expression of ESC signature genes, which clustered separately ( Fig. 3d and Supplementary  Fig. 6d ). This difference in cell heterogeneity can be further visualized in scatterplots showing the expression of individual DE and ESC genes ( We further examined the effects of JNKi using an optimized serum-free DE differentiation protocol 6, 39, 40 (see Methods). One day of JNKi treatment was sufficient to improve DE differentiation with this improved protocol as evaluated by flow cytometry analysis of CXCR4 and SOX17-GFP expression when compared with the untreated control ( Supplementary Fig. 7a-c) . We further demonstrated that 1 d of JNKi treatment improved DE differentiation across different hESC (HUES8, H1, HUES6) and hiPSC (CV, BJ) lines under this optimized differentiation condition ( Fig. 3g and Supplementary Fig. 7d ). Different culture media could influence the outcome of DE differentiation. Our work shows that JNK inhibition improves DE differentiation in both serum-free and serumcontaining conditions.
Furthermore, DE cells from the 1-d JNKi-treated condition formed a higher percentage of PDX1 + NKX6.1 + pancreatic progenitor cells or NKX2.1 + FOXA2 + lung progenitor cells as shown by immunostaining and quantified by flow cytometry analysis ( Fig. 3h-k) . Additional pancreatic (NEUROD1, MNX1 and NGN3) or lung (FOXP2 and CPM) progenitor markers were upregulated in the JNKi-treated condition by RT-qPCR analysis ( Supplementary  Fig. 7e,f ). These results demonstrate that JNK inhibition improves DE differentiation, which leads to more robust subsequent differentiation to the pancreatic and lung lineages.
JUN impedes chromatin landscape remodeling during ESC-DE differentiation.
The Nodal-TGF-β-SMAD2/3 signaling axis is required for both hESC pluripotency maintenance and DE differentiation 3, 10, 11 . SMAD2/3 binding patterns have been shown to be associated with lineage-specific TFs [41] [42] [43] . We performed SMAD2/3 chromatin immunoprecipitation sequencing (ChIP-seq) at the ESC and DE stages, and analysis of differentially bound regions identified OCT4/NANOG as the most enriched motif among SMAD2/3-bound regions at the ESC stage, and SMAD and GATA as the most enriched motifs at the DE stage ( Supplementary Fig. 8a,b) . This observation suggests that SMAD2/3 binds cooperatively with OCT4/NANOG at the ESC stage and becomes free to occupy its own binding sites or co-occupy with GATA6 at the DE stage.
To investigate the effect of JNK inhibition on chromatin remodeling during DE differentiation, we performed assay for transposaseaccessible chromatin sequencing (ATAC-seq) on hESCs after 1 d of DE differentiation (DE D1, corresponding to the primitive streak stage). Using two de novo discriminative motif algorithms, HOMER 44 and MotifSpec
45
, we found AP-1 and TEAD binding sites were enriched in regions with decreased accessibility on JNK inhibition (Fig. 4a) . We also found GATA and SMAD binding sites were enriched in regions with increased accessibility on JNK inhibition. Using an alternative gapped k-mer (oligomers of length k)-based approach, we trained gapped k-mer support vector machine (gkm-SVM) 46 on regions with increased versus decreased accessibility and identified significant feature weights for k-mers matching these same binding sites (AP-1, TEAD, GATA, SMAD), which in combination could account for almost all of the changes in the chromatin accessibility between these two conditions (area under the receiver operating curve (AUROC) = 0.923) (Supplementary Dataset 4) .
Next, we performed SMAD2/3 and GATA6 ChIP-seq analysis at the DE stage and found that indeed regions with increased accessibility on JNK inhibition (DE D1) showed significant GATA6 and SMAD2/3 binding at the DE stage (Fig. 4b,c) . These results suggest that JNK inhibition promotes the access of SMAD2/3 and GATA6 to DE enhancers during the ESC-DE transition. Importantly, as suggested by the motif analysis, regions with decreased accessibility on JNK inhibition showed enrichment of JUN binding at the ESC stage, indicating a direct role of JUN in regions that lost rather than gained chromatin accessibility. We speculate that JNK inhibition may promote ESC-DE transition through accelerating the loss of chromatin accessibility at ESC enhancers. Supporting this notion, regions with decreased accessibility on JNK inhibition also showed enriched OCT4 and SMAD2/3 binding at the ESC stage (Fig. 4b,c) .
The association of JUN and OCT4 binding in regions with decreased accessibility on JNK inhibition prompted us to examine the global pattern of JUN and OCT4 binding in undifferentiated hESCs. We observed significant overlap (P < 3.89 × 10
) between OCT4 and JUN binding (Supplementary Fig. 8c ): ~60% of JUNbound sites were cobound by OCT4. Focusing on the strongest OCT4-bound sites (using MACS2 FDR q = 1 × 10 −6 instead of the default q = 0.05 for peak calling), the overlap is still significant (P < 1 × 10 −300
): ~28% of JUN-bound sites were cobound by OCT4 (Fig. 4d) Supplementary Fig. 8d ). Indeed, at the ESC stage, cooccupancy of JUN, OCT4, NANOG and SMAD2/3 was observed at enhancers of ESC genes (for example, OCT4, NANOG and SOX2), and JNK inhibition during DE differentiation decreased the chromatin accessibility at these enhancers (Fig. 4f) . Meanwhile, we observed co-occupancy of SMAD2/3 and GATA6 at enhancers of DE genes (for example, SOX17, GATA6 and CXCR4), and JNK inhibition during DE differentiation increased the chromatin accessibility (Fig. 4f) . Together, these findings suggest a direct role for JUN binding in maintaining chromatin accessibility at ESC enhancers that begin to be decommissioned during differentiation.
JUN impedes SMAD2/3 reconfiguration during ESC-DE differentiation.
To better understand the effect of JUN on the enhancer landscape during DE differentiation, we focused on the top OCT4-bound ESC enhancers (9,248, excluding promoter regions) and the top GATA6-bound DE enhancers (9,248) for further analyses (Fig. 5a ). NANOG binding was strongly enriched at the ESC enhancers as expected, and there was a dramatic reconfiguration of SMAD2/3 binding during the ESC-DE transition from OCT4-bound ESC enhancers to GATA6-bound DE enhancers (Fig. 5a ). When comparing OCT4-bound regions with high versus low JUN ChIP-seq signals, we found a strong correlation of SMAD2/3 occupancy with the JUN high group, which also showed stronger OCT4
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and NANOG signals compared with the JUN low group ( Fig. 5a and Supplementary Fig. 8e ). Together, these analyses uncovered a strong association of JUN binding to ESC enhancers, especially those that are also occupied by SMAD2/3.
Next, we analyzed the effects of JNK inhibition on these ESC and DE enhancers. JNK inhibition (DE D1) decreased chromatin accessibility at OCT4 + JUN high ESC enhancers and increased chromatin accessibility at GATA6
+ DE enhancers (Fig. 5a,b) . Such reciprocal ). e, The boxplots show the average ATAC-seq, SMAD2/3, OCT4, H3K27ac (GSM733718) and p300 (GSM803542) ChIP-seq signals 61 over the OCT4
− regions in ESCs. Boxes show interquartile range, whiskers show fixed multiples of interquartile range and solid line shows median. f, Relevant ATAC-seq and ChIP-seq tracks of ESC genes (OCT4, NANOG and SOX2) and DE genes (SOX17, GATA6 and CXCR4). Genomic coordinate from GRCh37 (human hg19) for each gene is labeled. Representative images are from two independent experiments. bp, base pair.
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effects were also observed on SMAD2/3 binding at ESC and DE enhancers, respectively (Fig. 5a,c) , indicating that JNK inhibition promotes the reconfiguration process of the SMAD2/3 binding pattern from ESC to DE enhancers. Similar reciprocal effects on chromatin accessibility and SMAD2/3 occupancy were also observed when examining ESC and DE enhancers that are also bound by SMAD2/3, or when broadly examining SMAD2/3-occupied regions (including promoters) at the ESC and DE stages irrespective of OCT4 or GATA6 occupancy ( Supplementary Fig. 8f ). These effects were not due to an effect of JNK inhibition on SMAD2 protein expression or phosphorylation at Ser 465/467 or Ser 245/250/255 ( Supplementary Fig. 8g ).
The tight correlation of JUN and SMAD2/3 binding at the ESC stage prompted us to directly examine the global effect of SMAD2/3 occupancy on JNK inhibition at DE D1. We found that regions with decreased SMAD2/3 binding on JNK inhibition showed enrichment ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp ±500 bp 
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of JUN, SMAD2/3 and OCT4 binding at the ESC stage and decreased ATAC-seq signal after JNK inhibition, whereas regions with increased SMAD2/3 binding showed enrichment of SMAD2/3 and GATA6 binding at the DE stage and increased ATAC-seq signal after JNK inhibition (Fig. 5d,e and Supplementary Fig. 8h ). Corresponding changes were observed at many individual ESC and DE enhancers ( Fig. 4f and Supplementary Fig. 8i ). In addition, JNKi treatment significantly increased SMAD2/3 and GATA6 cooccupancy (P < 2 × 10 −62
; Supplementary Fig. 8j ). Further supporting a direct causal relationship between decreased JUN binding and decreased SMAD2/3 binding at ESC enhancers, HOMER, MotifSpec and gkm-SVM analysis showed that regions with decreased SMAD2/3 binding on JNK inhibition were enriched with AP-1 and TEAD binding sites, whereas regions of increased SMAD2/3 binding were enriched with GATA and SMAD binding sites, and k-mers matching these same binding sites can account for most of the changes in the SMAD2/3 binding (AUROC = 0.962; Fig. 5f and Supplementary Dataset 4) .
Lastly, we investigated the transcriptional consequences of JUN binding at ESC enhancers. JUN, SMAD2/3, OCT4 and NANOG GATA6 
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showed co-occupancy at cis-regulatory regions of many ESC genes including OCT4, NANOG, SOX2, PRDM14 and others (Fig. 5g) . The expression levels of these genes at the ESC stage were not affected by genetic inactivation of the JNK pathway (MKK7 KO) (Fig. 5h) . However, after DE differentiation, they were further downregulated in MKK7 KO DE cells compared with WT DE cells (Fig. 5h) . Globally, the most decreased JUN binding sites from ESC to DE D1 were enriched near genes with the most decreased expression during the ESC-DE transition (Supplementary Fig. 8k ). Taken together, we show that JUN, SMAD2/3 and OCT4/NANOG co-occupy ESC enhancers, and JUN binding impedes the decommissioning of ESC enhancers and the corresponding downregulation of ESC genes during DE differentiation; inhibition of JUN binding accelerates the reconfiguration of the SMAD2/3 binding pattern from an ESC to DE signature and promotes the establishment of the DE enhancer landscape (Fig. 6a) . (Fig. 6b,c) . Conversely, DE TFs activate their own transcription but negatively regulate ESC TFs. Activin A produces a transient activation of DE TFs, modeled as an impulse. A low Activin A impulse activates GATA6 but does not stimulate GATA6 sufficiently to produce transitions to the stable GATA6 high DE state. When the autoactivation of OCT4 is weakened by 15%, the same low Activin A impulse is now sufficient to stimulate 7 out of 10 of the simulations into the high GATA6 high DE state. We can then simulate the rate at which cells transition to the DE state under varying Activin A doses (Fig. 6d) . If JNK inhibition reduces either transcriptional activation of the ESC genes or the binding of ESC TFs to their autoregulatory enhancers, the model predicts a reduction in the Activin A dose required for efficient transition to the DE state.
Stochastic simulations of ESC-DE transition.
We tested this prediction by performing an Activin A dose titration experiment using the HUES8 SOX17 GFP/+ reporter line. The efficiency of DE differentiation depended on the Activin A concentration. JNK inhibition did not eliminate the requirement for Activin A, but enabled efficient DE differentiation with lower Activin A doses (Fig. 6e) . JNK inhibition also promoted differentiation of H1 hESCs treated with a low Activin A dose (20 ng ml −1 , instead of the typical 100 ng ml −1 ) ( Supplementary Fig. 9a,b) . Similar effects were observed with genetic inactivation of the JNK pathway members MKK7 and JUN ( Supplementary Fig. 9c,e) . Overall, these results together with the mathematical modeling and genomic studies support the concept that JNK inhibition during DE differentiation destabilizes the ESC enhancers that were maintained by the cobinding of JUN, SMAD2/3 and OCT4/NANOG, thereby accelerating the establishment of the DE enhancer landscape and lowering the Activin A dose requirement for efficient DE differentiation.
Discussion
Both hESC self-renewal and DE differentiation involve Nodal-TGF-β signaling via the SMAD2/3 complex. During differentiation, SMAD2/3 chromatin binding undergoes a dramatic reconfiguration from ESC to DE enhancers. Our comprehensive screens using two independent CRISPR libraries uncovered the JNK-JUN pathway as a key barrier from pluripotency to DE differentiation. Unlike a typical signaling pathway that inhibits differentiation, the JNK-JUN pathway does not act through directly inhibiting the DE enhancers. Instead it primarily acts on ESC enhancers. JUN and OCT4 co-occupy many enhancers at the ESC stage, and JUN-bound enhancers exhibit higher levels of chromatin accessibility, H3K27ac, and p300 binding. JNK inhibition during DE differentiation accelerates the destabilization of the pluripotency network, as supported by the decreased chromatin accessibility at ESC enhancers. This is accompanied by decreased SMAD2/3 occupancy at ESC enhancers; thus, JNK inhibition also facilitates the reconfiguration of SMAD2/3 chromatin binding. Our mathematical modeling further supports the notion that the JNK-JUN pathway safeguards the pluripotency gene-regulatory network, and also predicts that JNK inhibition during DE differentiation would reduce the Activin A dose requirement, which was verified experimentally.
The similar phenotypes observed in JUN and MKK7 KO hESCs argue that JUN is the predominant AP-1 TF involved in DE differentiation, although potential overlapping requirements of additional AP-1 TFs cannot be excluded. It is of great interest to determine whether the JNK-JUN pathway also inhibits DE in vivo. It is not feasible to directly examine the roles of the JNK-JUN pathway in gastrulating human embryos, and the exact role of the JNK-JUN pathway in mouse DE differentiation is unclear. Jun KO mouse embryos show developmental arrest at around embryonic day 12, but earlier phenotypes during DE differentiation have not been examined 47, 48 . Deletion of Jnk1/2 or Jun in mouse ESCs (mESCs) did not have a significant effect on early endoderm gene expression in spontaneous embryoid body and retinoic acid-induced differentiation assays, but a specific effect on DE differentiation has not been examined 49, 50 . More quantitative experiments are needed to characterize the exact involvement of the JNK-JUN pathway in mouse embryos during the crucial time window of pluripotency exit and DE differentiation. The mouse KO phenotypes may also differ from those observed in hESC-directed differentiation because of potential compensatory mechanisms in vivo or species-specific gene requirements.
Recent studies on somatic cell reprogramming show that the AP-1 motif is strongly associated with chromatin regions undergoing closing during the initial phase of reprogramming mouse fibroblasts to iPSCs [50] [51] [52] . Further overexpression and loss-of-function studies show that AP-1 TFs such as Jun and Fra1 act as barriers to the acquisition of the pluripotent state. Here we show that in pluripotent hESCs, JUN binding strongly associates with OCT4-bound ESC enhancers with higher enhancer activities. Instead of inhibiting the acquisition of the pluripotent state as shown in the context of somatic cell reprogramming, JUN impedes the exit from the pluripotent state. It may seem counterintuitive that JUN inhibits both the acquisition and the dissolution of the pluripotent state. This paradox can be explained by a unifying theme that AP-1 TF JUN is a guardian of lineage identity, which is the ESC identity in the context of pluripotency dissolution, or the initial fibroblast identity in the context of pluripotency acquisition. This mechanism is consistent with findings from previous studies demonstrating that AP-1 binds together with lineage-specific pioneer factors at enhancers to facilitate recruitment of the SWI/SNF complex and potentiate chromatin accessibility and co-activator recruitment in other lineages 33, 53, 54 . In macrophages, the AP-1 motif is also found through Hi-C genomic data analysis to be highly enriched in the activation hubs that connect multiple enhancers to promoters 55 . Our work demonstrates the power of using unbiased CRISPR screens to identify the barriers of hESC differentiation. JNKi treatment not only improved the differentiation efficiency of DE, but also improved DE-derived pancreatic and lung lineage cells. Thus, targeting negative regulators of DE differentiation represents a rational strategy to improve differentiation to endoderm-derived lineages. Other groups have successfully improved pancreatic and lung differentiation by focusing on differentiation at later stages 56 
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+ cells from ~20% to ~70% by flow cytometry after only 9 d of differentiation, demonstrating the importance of improving DE differentiation for generating DE-derived cell types. Our screening strategy can be extended to systematically interrogate sequential lineage decisions leading to the formation of mature cell types such as pancreatic β cells. Such screens may also benefit from inducible expression of Cas9 (ref. 16 ) or dCas9-KRAB 60 during differentiation to interrogate the temporal control of human development. Knowledge gained from unbiased screening efforts such as ours can contribute to the understanding of human development and improve hESC/hiPSC-directed differentiation for disease modeling and regenerative medicine.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0408-9. 
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Methods
Culture of hESCs and hiPSCs. This study used three hESC lines, HUES6, HUES8 and H1 (NIHhESC-09-0019, NIHhESC-09-0021 and NIHhESC-10-0043) and two hiPSC lines (BJ and CV). The generation of the iCas9 lines from HUES8 and H1 cells was previously described 6, 16 . Undifferentiated hESCs and hiPSCs were maintained as previously described 62 in the chemically defined feeder-free, serumfree E8 condition (A1517001; Thermo Fisher Scientific) on polystyrene plates coated with human recombinant vitronectin (A14700; Thermo Fisher Scientific) at 37 °C with 5% CO 2 . hESCs/hiPSCs were dissociated with 0.5 mM EDTA and split every 3-4 d at a 1:10-1:15 ratio. Cells were routinely confirmed to be mycoplasmafree by the Memorial Sloan Kettering Cancer Center (MSKCC) Antibody and Bioresource Core Facility. All experiments were approved by the Tri-SCI Embryonic Stem Cell Research Oversight Committee.
Generation of the HUES8 SOX17
GFP/+ reporter line. The HUES8 iCas9 cell line carries a puromycin resistance gene 16 . Because the GeCKO v.2 and Brunello library also relies on puromycin selection, we first transfected HUES8 iCas9 cells with an in vitro-transcribed gRNA (Supplementary Table 2 ) to knock out the puromycin resistance gene. We then established the HUES8 SOX17 GFP/+ iCas9 line using a selection-free knock-in strategy 17 ( Supplementary Fig. 1b) . Correct targeting was verified by Southern blotting as previously described 16 . The sequence for the 5′ external probe is shown in Supplementary Table 3 . The probe was synthesized by PCR using the PCR DIG probe Synthesis Kit (11636090910; Roche Applied Sciences). A total of 20 μg genomic DNA was digested with XmnI, which produced a 3,974-base pair DNA fragment with the GFP insertion and a 3,188-base pair DNA fragment without the GFP insertion ( Supplementary Fig. 1c ). Southern blotting identified one clonal cell line, in which the stop codon of one SOX17 allele was replaced by the 2A-GFP sequence, and the other SOX17 allele remained WT. This HUES8 SOX17
GFP/+ iCas9 cell line maintains a normal karyotype ( Supplementary Fig. 1g ). Genomic DNA genotyping revealed no de novo mutation in the TP53 coding sequences in the HUES8 SOX17 GFP/+ iCas9 cell line.
Production of the lentiviral library. Human CRISPR libraries GeCKO v.2 and
Brunello were obtained from Addgene (1000000049 and 73178) 20, 21 . A total of 50 μg CRISPR library plasmids with 20 μg lentiviral packaging vector psPAX2 and 5 μg vesicular stomatitis virus G (VSV-G) envelope expressing plasmid pMD2.G (Addgene plasmid 12260 and 12259) were transfected with the JetPRIME (89137972; VMR) reagent into 293T cells to pack the lentivirus. Viral supernatant was collected, filtered, aliquoted, and stored at −80 °C. We used lentivirus infection efficiency to estimate the multiplicity of infection (MOI) according to the formula
, where m is the MOI, n is the occurrence of event that virus enters into cells, e is exponential growth constant, and P (n) is the probability that a cell will get infected by n viruses. The infection efficiency can be viewed as the probability of being infected, which equals 1 − P(0). When MOI is equal to 0.36, the infection efficiency (1 − P (0)) is 30%, and the probability of a cell getting two or more viruses is 16.28%. To determine the viral titer for an infection efficiency rate of 30%, 0.15 million HUES8 SOX17 GFP/+ hESCs per well were infected with different amounts of virus (0-20 μl) in duplicates in six-well plates. Forty-eight hours later, puromycin (0.5 μg ml −1 ) was added into one set of the cells to select infected cells. After 48 h of treatment of puromycin, uninfected control cells were killed by puromycin selection. The ratio of the cell number of the selected set (treated with puromycin) over the unselected set (not treated with puromycin) was calculated to determine the infection efficiency. The amount of virus needed for the 30% infection efficiency in the six-well format is scalable to a 150-mm plate by a factor of 15.
Genome-wide CRISPR screens.
A minimum of 200-fold library coverage is typically recommended for screens based on basic phenotypes such as cell survival and growth. Considering the relatively complex nature of a screen for lineage regulators, we aimed for an ~1,000-fold coverage to maximize sensitivity. Two hundred million HUES8 SOX17 GFP/+ iCas9 cells were harvested and infected with the lentiviral library at a low MOI of 0.36 at D0 in 150-mm plates (100 plates total). A total of 6 μg ml −1 protamine sulfate was added on the first day of infection to enhance the infection efficiency. Next, infected cells were treated with 2 μg ml −1 doxycycline (D1-D7) and 0.5 μg ml −1 puromycin (D2-D7). On D7, cells were treated with TrypLE Select (12563029; Thermo Fisher Scientific), and 120 million cells were plated into 150-mm plates (59 plates total). On D8, cells were switched from the maintenance E8 medium to the DE differentiation medium (described in the DE differentiation subsection). After 3 d of DE differentiation (D8-D11), cells were dissociated using TrypLE Select and sorted using FACSAria according to GFP expression. Sorted GFP + and GFP − cells were pelleted, and genomic DNA was immediately extracted using the QIAGEN Blood & Cell Culture DNA Maxi Kit (13362; QIAGEN).
HiSeq and data analysis.
A two-step PCR method was performed to amplify the gRNA sequence for HiSeq. For the first step, ~380 μg DNA per sample from GeCKO screen and ~504 μg DNA per sample from Brunello screen (6.6 μg genomic DNA per 1 million cells) were used to perform PCR using Herculase II fusion DNA polymerase (600679; Agilent) to achieve a 1,000-fold converge of the GeCKO and Brunello libraries. Primer sequences to amplify lentiGuide-puro for the first PCR are shown in Supplementary Table 3 (F1 and R1 ). In total, we performed 38 separate 100-μl reactions with 10 μg genomic DNA per sample for 18 cycles and combined the resulting amplicons. For the second step, 5 μl of the product from the first PCR was used in a 100-μl PCR for 24 cycles with primers to attach Illumina adapters for barcoding. Primers used in this reaction are shown in Supplementary  Table 3 (F2 and R2 ). Gel-purified amplicons from the second PCR were quantified, mixed, and sequenced using Illumina HiSeq 2500 by MSKCC Integrated Genomics Operation. Raw FASTQ files demultiplexed by MSKCC Integrated Genomics Operation were further processed to contain only the unique gRNA sequences, and the processed reads were aligned to the designed gRNA sequences from the library using the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/). The read counts were further normalized to total reads of that sample to offset differences in read depth. Z-score of each gRNA and gene was calculated as illustrated in Supplementary Fig. 2a,b. Hit validation and the lentiCRISPR approach. The H1 iCas9 line 6 was used for most validation experiments. Some hits were tested again in HUES8 SOX17 GFP/+ iCas9 cells. The differentiation outcome was evaluated by directly measuring intracellular SOX17 expression through flow cytometry instead of relying on the GFP reporter. For hit validation and all experiments using the lentiCRISPR approach, gRNAs were cloned into lentiGuide-puro (52963; Addgene) following published protocols 20 . The lentiGuide-puro construct expresses a puromycin resistance gene, allowing the selection of infected cells through puromycin treatment. One microgram lentiGuide, 0.1 μg VSVG and 0.4 μg PAX2 plasmids were transfected with the JetPRIME (89137972; VMR) reagent into 293T cells to pack lentiviruses. Viral supernatant was collected, filtered, aliquoted and stored at −80 °C. An MOI of ~0.30-0.36 was used for the infection of the iCas9 cell line with different lentiCRISPR viruses. Cells were treated with 2 μg ml −1 doxycycline (D1-D7) to induce Cas9 expression and 0.5 μg ml −1 puromycin to eliminate non-infected cells (D2-D7). On D7, cells were treated with TrypLE Select, and 0.1 million cells per well were plated in duplicate sets in a six-well plate. One set was used for DE differentiation the next day. The other set was cultured in E8 media for maintenance until the second repeat of differentiation. gRNA targeting sequences selected from the GeCKO v.2 library are listed in Supplementary Table 2 .
Two gRNAs per gene were tested for validation. Two non-targeting gRNAs were used as WT controls.
Generation of clonal KO hESC lines.
Clonal KO lines were created as previously described 16 with some modifications. H1 iCas9 cells were infected with lentiviruses expressing MKK7 or JUN targeting gRNAs made from the lentiGuide-puro construct (Supplementary Table 2 ) on D0. Next, cells were treated with 2 μg ml −1 doxycycline (D1-D7) and 0.5 μg ml −1 puromycin (D2-D7). On D7, infected hESCs were dissociated to single cells using TrypLE Select. Five hundred cells were plated into one 100-mm tissue culture dish with 10 ml E8 medium supplemented with 10 μM Rho-associated protein kinase inhibitor Y-27632 (S1049; Selleck Chemicals) for colony formation. After 10 d of expansion, 50 colonies were picked into individual wells in a 96-well plate. Genomic DNA was extracted for PCR genotyping. Primers used for PCR and sequencing are listed in Supplementary Table 3. DE differentiation. All DE differentiation experiments were performed on hESCs grown on vitronectin. For the CRISPR screens and screening hit validation, cultured hESCs/hiPSCs were grown to 80−90% confluence and then treated with TrypLE Select for dissociation into single cells. Typically, 0.15 million hESCs/ hiPSCs were plated in one well of the six-well plates with 10 μM Y-27632 in 2 ml E8 medium. For the H1 line, we typically plated 0.1 million cells to accommodate the higher proliferation rate compared with other lines. For differentiation in 150-mm dishes, we multiply the numbers by a factor of 15 based on the numbers from sixwell plates. Twenty-four hours later, cells were washed with PBS once and culture medium was changed to Advanced RPMI (12633012; Thermo Fisher Scientific) with penicillin-streptomycin (15070063; Thermo Fisher Scientific), GlutaMAX (35050079; Thermo Fisher Scientific), 0.003% BSA 15260037; Thermo Fisher Scientific), 5 μM CHIR99021 (4423; Tocris) and 100 (high) or 20 (low) ng ml Activin A (12014E (PeproTech); BP08001 (Bon Opus Biosciences)). Over the next 2 d, culture medium was changed to Advanced RPMI with penicillin-streptomycin, GlutaMAX, 0.2% FBS and 100 or 20 ng ml −1 Activin A. Although FBS was used in the initial GeCKO library screen, we have since found that FBS is not essential for DE differentiation. Thus, we omitted FBS in the Brunello screen. For JNK inhibition, 1 μM JNK-IN-8 (S4901; Selleck Chemicals) was added at the indicated time window, whereas equal concentration of dimethylsulfoxide was used as a vehicle control.
Serum-free DE differentiation and subsequent pancreatic and lung differentiation. We performed DE differentiation using an optimized serum-free protocol 39, 62 followed by pancreatic or lung lineage differentiation. For serum-free DE differentiation, 0.3 million HUES8, H1, HUES6 and BJ iPSCs were plated in E8 medium in one well of a six-well plate coated with human recombinant vitronectin
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differentiation because of its slower growth rate. Cells were washed with PBS once, and culture medium was changed to MCDB131 (10372-019; Life Technologies) with 1× GlutaMAX, 0.5% BSA (7500804; Lampire Biological Products), 1.5 g l −1 NaHCO 3 and 10 mM glucose (S22060; Thermo Fisher Scientific), supplemented with 5 μM CHIR99021 and 100 or 20 ng ml −1 Activin A for 1 d. On the second day, the medium was supplemented with 0.5 μM CHIR99021 and 100 or 20 ng ml −1 Activin A as specified. On the third day, the medium was supplemented with 100 or 20 ng ml −1 Activin A only. For pancreatic lineage differentiation 6, 39, 40, 62 , ~1 million HUES8 hESCs were plated for DE differentiation as described earlier. DE cells were washed with PBS and cultured in MCDB131 with 1× GlutaMAX, 0.5% BSA, 1.5 g l −1 NaHCO 3 , 10 mM glucose supplemented with 0.25 mM vitamin C (A4544; Sigma), 50 ng ml Tocris) 57 from D3 to D6. Then, from D6 to D9, cells were grown in lung base medium containing 100 ng ml −1 human recombinant BMP4 (314-BP-010; R&D Systems), 0.5 μM ATRA (Sigma) and 3 μM CHIR99021 (ref. 63 ). The medium was changed every day.
Neuroectoderm differentiation. hESCs cultured in E8 were disaggregated using TrypLE Select for 5 min and washed using E8 medium. The cells were plated on Matrigel (354234; BD)-coated dishes in E8 medium with 10 μM Y-27632 at a density of 180,000-200,000 cells cm −2 . After 1 d of culture in E8 medium, differentiation was initiated by switching to KO serum replacement (KSR) media with 10 μM TGF-β receptor inhibitor SB431542 (161410; Tocris) and 100 nM BMP inhibitor LDN193189. On D1 and D2 of differentiation, the medium was removed and fresh KSR with 10 μM SB431542 and 100 nM LDN193189 was added. Starting on D4 of differentiation, an increasing amount of N2 medium was added to the KSR media every 2 d, while maintaining 10 μM SB431542 and 100 nM LDN193189. On D4, a 3:1 mixture of KSR/N2 medium was added. On D6, a 1:1 mixture of KSR/N2 media was added, and on D8, a 1:3 mixture of KSR/N2 media was added. The cells were isolated for flow cytometry analysis on D4, D6, D8 and D10 of differentiation and for immunostaining on D10 of differentiation. KSR medium contains Knockout DMEM (10829018; Thermo Fisher Scientific), Knockout Serum Replacement (10828028; Thermo Fisher Scientific), 1× MEM Non-Essential Amino Acids (11140050; Thermo Fisher Scientific), 1× GlutaMAX (35050079; Thermo Fisher Scientific) and 2-mercaptoethanol (21985023; Thermo Fisher Scientific). N2 medium contains DMEM/F12 medium (12500-062; Thermo Fisher Scientific), glucose (G8270; Sigma), sodium bicarbonate (S5761; Sigma), putrescine (P5780; Sigma), progesterone (P8783; Sigma), sodium selenite (S5261; Sigma), apo-transferrin (T1147; Sigma) and insulin (I2643; Sigma).
Flow cytometry. Cells were dissociated using TrypLE Select and resuspended in FACS buffer (5% FBS, 5 mM EDTA in PBS). First, cells were stained with surface antibody (CXCR4-APC) with LIVE/DEAD violet dye (L34955, 1:1,000; Molecular Probes) for 30 min at 4 °C. After washing with FACS buffer, cells were fixed and permeabilized in 1× fixation/permeabilization buffer (00-5523-00; eBioscience) for 30 min at room temperature. After fixation and permeabilization, cells were stained with intracellular antibody (SOX17-PE, GATA6-PE, GATA4-Alexa 647, NKX6.1, PDX1, NKX2.1) in permeabilization buffer (00-5523-00; eBioscience) for 30 min at room temperature. After washing with permeabilization buffer, cells were resuspended in permeabilization buffer with fluorescence-conjugated secondary antibodies for 30 min at room temperature. After staining, cells were washed, suspended in FACS buffer and analyzed using BD LSRFortessa or BD LSRII. Flow cytometry analysis and figures were generated in FlowJo v.10. Detailed information of antibodies used is listed in Supplementary Table 4 . The FACS gating strategy is shown in Supplementary Fig. 1h .
RNA isolation and reverse transcription-quantitative PCR (RT-qPCR).
Cell pellets were lysed in TRIzol (15596018; Thermo Fisher Scientific). RNA was extracted from TRIzol lysate using the RNeasy Mini Kit (74106; Qiagen). cDNA was produced using a High Capacity cDNA Reverse Transcription Kit (43814; Applied Biosystems). qPCR was performed in triplicate using Absolute Blue QPCR SYBR Green Mix with low ROX (AB4322B; Thermo Fisher Scientific) on the ABI PRISM 7500 Real Time PCR System (Applied Biosystems) using the following protocol: 15 min at 95 °C followed by 40 Fig. 8k ) are preferentially located closer to the transcription start site of ESC-expressed genes farther from DE-expressed genes, following the similar analysis in figure 5 , supplement 1 of Mo et al. 68 .
Single-cell RNA-seq (Drop-Seq) and analysis. DE cells were washed with PBS once and treated with TrypLE for 5 min. E8 medium was added to stop the digestion. Dissociated single cells were resuspended in PBS with 0.01% BSA, passed through a 40-μm filter and counted. Cell concentration was adjusted to 100-120 cells μl −1 with >90% viability (in 1 ml volume). Cell suspension were kept on ice and transferred to the Weill Cornell Genomics and Epigenomics Core Facility for Drop-Seq. Drop-Seq experiment procedure follows the protocol published by the McCarroll laboratory (v.3.1, 18 December 2015) 38 (http:// mccarrolllab.com/download/905/). The sequenced reads were processed and turned into a digital expression matrix using the Drop-Seq computational pipeline (v.1.2) of the McCarroll laboratory (http://mccarrolllab.com/dropseq/). The reference genome was GRCh38, and the gene annotation was from Ensembl release 76. The resulting count matrix was filtered to remove lowly covered cells and rarely captured transcripts, normalized for differences in sequencing depth and denoised using the MAGIC algorithm Immunofluorescence staining. Cells were fixed in 4% paraformaldehyde (50980495; Thermo Fisher Scientific) for 10 min at room temperature. After washing with PBST (PBS with 0.2% Triton X-100) three times for 5 min each, cells were blocked in 5% donkey serum in PBST buffer for 5 min. Cells were incubated with primary antibodies for 1 h at room temperature. After washing with PBST three times for 5 min each, cells were incubated with fluorescence-conjugated secondary antibodies and 0.2 μg ml −1 DAPI (32670-5 mg-F; Sigma) for 1 h at room temperature. After washing with PBST three times for 5 min each, images were taken with equal exposure for the same field. All primary and secondary antibodies used are listed in Supplementary Table 4 .
Western blot. Cell pellets were snap frozen in liquid nitrogen and lysed in cell lysis buffer (9803; Cell Signaling Technology) with proteinase/phosphatase inhibitors (5872; Cell Signaling Technology) and 1 mM PMSF (ICN19538105; MP Biomedicals). Proteins were precleared by centrifugation at 14,000g for 10 min at 4 °C. Protein concentration was determined by the Bradford Protein Assay (500-0202; Bio-Rad). Equal amounts of protein were loaded into Bis-Tris 10% gel (Novex, NP0301BOX) and transferred to nitrocellulose membranes (Novex, LC2001). Membranes were blocked with 5% milk (for non-phosphorylated proteins) or 5% BSA (for phosphorylated proteins). Primary antibody was incubated overnight at 4 °C. Membranes were washed with TBST three times for 10 min each and incubated with secondary antibody for 1 h at room temperature. Membranes were washed with TBST three times for 10 min each. Enhanced chemiluminescence western blotting detection reagents (RPN2236 (Amersham) and 32106 (Thermo Fisher Scientific)) were used to visualize the protein bands. All antibodies and dilution factors are listed in Supplementary Table 4 .
ChIP-seq. ChIP was performed as previously described 70 . Cells were crosslinked with 1% formaldehyde (F1635; Sigma) at 37 °C for 15 min and quenched with 0.125 M glycine for 5 min at room temperature. Fixed cells were scraped off the plates in cold PBS buffer and washed twice in cold PBS buffer. Cell pellets were obtained by centrifugation at 3,000 revolutions per minute (r.p.m.) for 5 min at 4 °C and frozen in liquid nitrogen immediately before transferring to the −80 °C freezer. About 25 million cells were used for one ChIP reaction. Cell pellets were thawed on ice, resuspended in 1 ml SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8) containing proteinase and phosphatase inhibitor for one reaction in an Eppendorf tube and incubated on ice for 10 min. Sonication was performed on a Branson Sonifier 250 with a 20% amplitude setting for 5.5 min (10 s on/off pulsing). Sonication products were spun down at 14,000 r.p.m. at 4 °C for 10 min, and 1 ml supernatant-containing chromatin and DNA was transferred to a Falcon tube containing 9 ml ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8, 167 mM NaCl) with proteinase and phosphatase inhibitor. A total of 50 μl Dynabeads (10009D; Life Technologies) was added to samples and incubated at 4 °C with rotation for 1 h. After preclearing, Dynabeads beads were removed and 200 μl sample was collected as 2% input separately. Five-microgram antibodies were added to the precleared samples for overnight incubation at 4 °C with rotation. A total of 200 μl Dynabeads was added into one ChIP reaction and incubated for 4-6 h at 4 °C with rotation. Dynabeads were collected by centrifugation with 3,000 r.p.m. at 4 °C for 5 min and washed in 1 ml low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 150 mM NaCl) for 5 min at 4 °C with rotations. Then beads were washed in 1 ml high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 500 mM NaCl) twice and TE buffer (10 mM Tris-HCl, pH 8, 1 mM EDTA) twice for 5 min at 4 °C with rotation. After the last wash, beads were resuspended in 250 μl elution buffer (1% SDS, 0.1 M NaHCO 3 ) and incubated in a thermomixer: 850 r.p.m. for 15 min at 60 °C. Supernatant were collected and added with 5 M NaCl for overnight decrosslinking at 65 °C. A total of 10 μl 0.5 M EDTA, 20 μl 1 M Tris-HCl, pH 6.5, and 1 μl Proteinase K (20 mg ml ) were added to decrosslinked product and incubated for 1 h at 45 °C. DNA was isolated by using QIAquick PCR purification kit (Qiagen, 28104; QIAGEN). Libraries were prepared using the NEBNext ChIP-seq Library Prep Master Mix Set for Illumina (E6240L; New England Biolabs) and quality controlled using Agilent Technologies 2200 TapeStation to determine fragment size and PicoGreen (P7589; Life Technologies) to quantify the concentration. Samples were pooled and submitted to New York Genome Center for SE50 sequencing using Illumina HiSeq 2500.
ATAC-seq.
A total of 50,000 cells were pelleted by centrifugation at 1,500 r.p.m. for 5 min at 4 °C in 1 ml cold PBS buffer. Cell pellets were washed with 1 ml ice-cold ATAC buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 ) and lysed in 50 μl ATAC lysis buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.1% Nonidet P-40 or IGEPAL-Ca630) for 2 min on ice. Lysis was terminated by adding 1 ml cold ATAC buffer to the mixture. Nuclear pellets were extracted by centrifugation at 1,500 r.p.m. for 10 min at 4 °C and aspiration of supernatant to leave behind 22.5 μl sample liquid. A total of 2.5 μl Tagmentation Enzyme (transposase) and 25 μl Tagmentation Buffer (Illumina Nextera DNA Sample Preparation Kit) were added to the resuspended nuclear pellets. Reaction mixtures were transferred to PCR tubes and incubated for 30 min at 37 °C. Next, 0.2% SDS was added to the reaction mixtures and incubated for 5 min at room temperature. 2× Agencourt AMPure XP beads (A63881; Beckman Coulter) were used for sample purification. A total of 50 μl purified sample was mixed with 55 μl NEBNext Q5 Hot Start HiFi PCR Master Mix (catalog no. M0543L; NEB) and 5 μl Nextera primers 71 (the universal primer Ad1 mixed with the unique index primer 2.X at a final concentration of 25 μM). Amplification was performed as the following PCR program repeated 12 times: 65 °C, 5 min; 98 °C, 30 s; 98 °C, 10 s; 65 °C, 30 s. 1.5× AMPure XP beads were used for sample purification. The concentration and median fragment size were quality controlled by PicoGreen and Agilent D1000 screentape on the Agilent Technologies 2200 TapeStation, respectively. Samples were sequenced using Illumina HiSeq 2500 Paired-End 50 (PE50).
ATAC-seq and ChIP-seq analysis. We mapped reads to hg19 using bowtie2 (ref. 72 ) (paired reads for ATAC, local for ChIP) and ran MACS2 (ref. 73 ) to call peaks, and defined 300-base pair bound regions by extending 150 base pairs from each summit. Replicated ChIP-seq peaks were defined using MACS2 default parameters (default MACS2 FDR q-value parameter q = 0.05) and were filtered against hg19 ENCODE blacklisted regions. To demonstrate that our conclusions did not depend on the large number of MACS2 OCT4 default peaks (n = 45,320), we also defined a very stringent set of the strongest OCT4 peaks using q = 1 × 10 −6 (n = 11,743) for OCT4 only. In Fig. 4d and Supplementary Fig. 8c , the OCT4 + JUN + sets were defined by the intersection of the OCT4 and JUN replicated peaks (n = 8,198 for Supplementary Fig. 8c ; n = 3,800 for Fig. 4d) , and the OCT4 + JUN − sets were defined to be equal size sets of OCT4 + peaks with the lowest JUN ChIP-seq signal (n = 8,198 or n = 3,800). Both sets give consistent results.
When comparing signals across experiments, we normalized ATAC and ChIP-seq signals so columns in Figs. 4b and 5a,e had constant average signal across all bound regions shown, to correct for read depth and other technical variation. We evaluated the average signal (reads per base pair) within peak regions in all experiments using bigWigAverageOverBed 74 . We defined fixed size sets of differentially bound or accessible regions by their distance from y = x or the regression line for imbalanced read depth: N = 5,000 for ATAC (Fig. 4a) , N = 2,500 for SMAD2/3 DE WT versus JNKi (Fig. 5f ) and SMAD2/3 ESC versus DE (Supplementary Fig. 8a ).
To show the direct effect of JUN binding on changes in the enhancer landscape during the ESC-to-DE transition, in Fig. 5a we defined an OCT4 + ESC enhancer set using the stringent set of OCT4-bound replicated non-blacklisted peaks defined earlier (using q = 1 × 10
, n = 11,743) further filtered to remove promoters (<2 kb from transcription start site) (n = 9,248). We defined an equal size set of GATA6-bound distal DE enhancers consisting of the strongest GATA6 signal replicated MACS2 peaks filtered to remove promoters and blacklisted regions (n = 9,248).
We then split the ESC enhancers into equal JUN high and JUN low sets based on their JUN ESC ChIP-seq signal averaged from both replicates. Similarly, to show the direct effect of JNK inhibition on changes in chromatin accessibility and SMAD2/3 binding at DE D1, we defined an OCT4 + SMAD2/3 + ESC enhancer set from the overlap of the stringent q = 1 × 10 −6 OCT4 + ESC enhancers defined earlier with default q = 0.05 MACS2 SMAD2/3 peaks (n = 682), a GATA6 + SMAD2/3 + DE enhancer set from the overlap of the strongest GATA6 + DE enhancers with SMAD2/3 default DE peaks (n = 8,500) ( Supplementary Fig. 8f ), a SMAD2/3-bound ESC set from replicated default peaks (n = 5,511) ( Supplementary Fig. 8f ) and a SMAD2/3-bound DE set from the strongest SMAD2/3 DE peaks (n = 8,500) ( Supplementary Fig. 8f ), and calculated P values by Welch two-sample t test.
Significance of cobinding. We can estimate the P value for the significance of the cobinding of OCT4 and JUN at ESC by comparing with the null hypothesis that the two factors bind randomly among n = 105,269 ESC accessible genomic loci (MACS2 peaks on ESC ATAC). For default peak calling (Supplementary Fig. 8c ; nOCT4 = 45,230, nJUN = 13,474), the observed P value is P < 3.89 × 10 −224 for the overlap of OCT4 and JUN. For more stringent (q = 1 × 10 −6
) peak calling for OCT4 ( Fig. 4c; nOCT4 = 11,743 ), the observed P values are P < 1 × 10 −300 for the overlap of OCT4 and JUN.
We can calculate the significance of the increase in overlap of GATA6 and SMAD2/3 binding on JNK inhibition shown in Supplementary Fig. 8j with the following model. Because there is a large overlap of GATA6 and SMAD2/3 binding compared with the available genome, we can treat the overlap by modeling that GATA6 and SMAD2/3 are detected as binding independently at a small number of loci, N, and estimated this number of loci to make the overlap N GS = Np S p G match the observed N G , N S and overlap, N GS , where N G is the number of GATA6 bound regions, N S is the number of SMAD2/3 bound regions, N GS is the number of co-bound regions, and p G and p S are the probabilities of being bound by GATA6 or SMAD2/3, respectively. The observed overlap N GS = 9,567 between GATA6 and SMAD2/3 in DE D1 WT in Supplementary Fig. 8j is consistent with sampling from a population size of N = 49,475 genomic loci with p G = N G /N = 29,436/N and p S = N S /N = 16,080/N. Then with JNKi treatment, the number of total GATA6 and SMAD2/3 binding sites increases, but the overlap also increases. We needed to calculate the significance of the new overlap given that N G and N S both increase slightly. Under the hypothesis that p S and p G are constant and the binding is still independent at a new number of loci N′, the new denominator is N′ = 66,773 loci yielding expected binding N G = 39,728 and N S = 21,702, which is very close to the observed JNKi binding of 39,986 and 21,561 (by construction). This is a way of correcting for sequencing depth, technical variation, and so on. If the binding were independent in these loci as before, the expected overlap would be N GS = 12,912 ± 102. We use that variance to estimate the significance of the largerthan-expected observed overlap of N GS = 14,611, yielding P < 2 × 10 −62
. Sequence determinants of regulatory reconfiguration. We used complementary approaches to identify sequence features mediating changes in accessibility and binding. We used two discriminative motif identification algorithms, HOMER 44 and MotifSpec 45 trained on WT versus JNKi increased versus decreased accessibility and SMAD2/3 binding and vice versa. We also used a gapped k-merbased approach, gkm-SVM, trained on chromatin-accessible regions as described elsewhere 75 , which can describe how the full set of k-mers can in combination describe the changes in binding and accessibility. We reported in Figs. 4a and 5f and Supplementary Fig. 8a the highest AUROC single motifs found by either HOMER or MotifSpec and the hypergeometric P value associated with its differential enrichment. These motifs match the significant k-mers detected by gkm-SVM (Supplementary Dataset 4) . That the CV test set AUROC from gkm-SVM is high (0.923, 0.962, 0.991) and the large positive and negative weight k-mers match a relatively small set of motifs (AP-1, TEAD, GATA, SMAD) suggests that the differential binding and activity of these factors can directly account for the majority of the changes in the chromatin accessibility and binding landscape. In addition to test set cross-validation, the gapped k-mer vocabulary detected by gkm-SVM has been shown to be predictive of chromatin accessibility and massively parallel expression reporter assays in blind experimental comparisons 76, 77 . Whereas gkm-SVM trained on SMAD2/3 ESC versus DE-detected SMAD2/3 and GATA as the top k-mer weights in DE and OCT4 k-mers in ESCs (Supplementary Dataset  4) , standard motif enrichment methods identified OCT4 and SMAD2/3 motifs, but they were not the most highly scoring motifs (which were poly-A and GC rich).
Bifurcation model. We modeled the transition from ESC-DE as a minimal two-gene autoregulatory system with negative feedback between antagonistic representative ESC and DE TFs. This model is derived based on two interacting genes, their enhancers and their protein products, which we will call O = OCT4 and G = GATA6. However, the protein concentrations could represent a set of ESC TFs and DE TFs, and the interactions described as direct interactions here could be direct or indirect. Many of these interactions are supported by our ChIP-seq data and prior results. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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